In all three models, including the parental RPMI-8226 tumor cells, and RPMI-TGFB in vivo models with or without TGF-β injection, the armored B2ARM CAR T-cells eradicated tumors as well as B2 CAR T-cells. This evidence concerns the gene TGFB1 and neoplasm.